The second US trial attempted to replicate the good results produced in the Australian study.
This was not successful.
In the FDA submission half the diagnoses were abandoned; but even with the remaining three illnesses this was still rejected.
Now only one illness remains for the US. And RAP are right back to square one.
In terms of hoodwinking. Not the researchers … but the company … imo - yes.
When the second US trial results were announced TK claimed they were good. The market halved the share price. I think he was talking through his hat.
When the company suggested rapid commercialisation. Nonsense. The uptake was always going to require clinical utility and cost-effectiveness to be demonstrated. This is what is painfully slowly only now being addressed.
Hardly earth shattering insights on my part.
Having said all this buying RAP when it fails most badly has proved lucrative in the past. It is exactly what you want to see … bad news not making the share price drop. Strength in the register.
So this is a much better scenario than buying RAP on good news where the share price doesn’t rise because of weakness in the register.
But its all a bit of contrarian punt. Easier to say but harder to put in practice. Good luck to you pilko3 ... life isn't easy being a RAP supporter on HC these days ... hopefully the company does get its act together.
